Venetoclax

UChicago Medicine researchers made a strong impact at the 67th American Society of Hematology (ASH) Annual Meeting, held December 6–9, 2025, in Orlando, Florida. Highlights included innovative early-line applications of CAR T-cell therapy in multiple myeloma, cutting-edge investigations in acute leukemias, outcomes-focused studies in lymphoid and myeloid malignancies, and real-world data on the use of monoclonal antibodies. Faculty and trainees from UChicago Medicine joined international colleagues to share the latest updates from transformative research in blood cancers. Reflecting the breadth and depth of hematology research, the presentations covered novel therapeutic strategies, health services research and translational science. ASH 2025 awards and trainee recognition Three UChicago Medicine trainees were recognized with Abstract Achievement Awards for their contributions spanning survivorship, immunotherapy monitoring and supportive care. Samuel Yates, MD, MS , a two-time Abstract Achievement Award recipient, presented data from the NEOMA trial, an ongoing study testing structured nutrition and exercise during acute lymphoid leukemia (ALL) treatment to optimize muscle and fat composition in adolescent young adult (AYA) patients. He also shared results from another study demonstrating how comprehensive geriatric assessment can help predict treatment and survival outcomes in older adults with acute myeloid leukemia (AML). Abigail Sneider, MD, presented data from a clinical study exploring whether next-generation sequencing of bone marrow following B-cell maturation antigen -directed CAR T-cell therapy could characterize B-cell reconstitution and serve as a complementary diagnostic marker alongside minimal residual disease (MRD) testing in multiple myeloma. Habib El-Khoury, MD, shared findings on treatment-related clonal hematopoiesis in AYA survivors of ALL, highlighting the need to further study the long-term impact of small clonal population on therapy-associated complications. Nada Aboelella, PhD, a postdoctoral fellow in the laboratory of James LaBelle, MD, PhD , Professor of Pediatrics and Director of the Pediatric Stem Cell and Cellular Therapy Program at UChicago Medicine, received both the UChicago Biological Sciences Division Career Advancement for Postdocs Travel Award and the UChicago Medicine Comprehensive Cancer Center Trainee Associate Member Travel Award, to support her attendance at the ASH conference. In an oral presentation, she shared research demonstrating that adding venetoclax, a drug that targets BCL-2, during the CAR T-cell manufacturing process can enhance therapy effectiveness by improving the quality and potency of the final CAR T-cell product. Faculty presentations In a live symposium, Michael Bishop, MD , Professor of Medicine and Director of the Hematopoietic Stem Cell Transplantation Program at UChicago Medicine, joined by Luciano Jose Costa, MD, PhD, from the University of Alabama at Birmingham and Binod Dhakal, MD, MS, from the Medical College of Wisconsin, delivered in-depth analyses on the real-world clinical complications of CAR T-cell therapy in multiple myeloma (MM). Bishop emphasized the feasibility of administering CAR T-cell therapy in an outpatient setting and highlighted the importance of multidisciplinary collaboration to ensure successful outcomes. Megan McNerny, MD, PhD , Associate Professor of Pathology, chaired the session, “ Dissecting enhancer function in hematopoietic development and disease ,” which focused on how cutting-edge approaches like 3D functional genomics, genetic manipulations and computational biology are deepening our understanding of gene regulation in both normal and disease states. Austin Wesevich, MD, MPH, MS , Instructor of Medicine, presented compelling research showing that patients with sickle cell disease (SCD) were more likely to receive negative descriptors in their medical records, such as being labeled as “noncompliant” or “refusing care.” These stigmatizing labels were associated with fewer visits from care providers, longer hospital stays, and a higher likelihood of patients leaving the hospital without any medical advice, highlighting potential disparities in care delivery. In another presentation, he shows that patients with SCD were more likely to be labeled as having “refused” medications, despite physicians being less likely to adjust treatment plans when patients declined medication. It suggests potential bias in how patient decisions are recorded and respected. In an education session, “ Treatment refinement in multiple myeloma ,” Benjamin Derman, MD , Assistant Professor of Medicine, discussed whether maintenance therapy in MM can be safely discontinued using minimal residual disease (MRD)-guided strategies. He highlighted the potential benefits, such as improved quality of life, reduced side effects and better financial management with a practical framework for treatment discontinuation. In a poster session, he shared real-world data comparing the effectiveness of anti-CD38 monoclonal antibody therapies in treatment-naïve patients versus those previously exposed, showing limited benefit with retreatment. He also presented early results from an ongoing Phase II trial indicating high response rates and manageable toxicity using a reduced-intensity quadruplet regimen – belantamab mafodotin, carfilzomib, pomalidomide and dexamethasone in MM patients who relapsed after BCMA CAR T-cell therapy. Anand Patel, MD , Assistant Professor of Medicine and Medical Director, Inpatient Leukemia Service at UChicago Medicine, presented Phase II trial data showing that a tyrosine kinase inhibitor combined with inotuzumab ozogamicin achieved deep MRD-negative remissions in newly diagnosed Philadelphia chromosome–positive ALL, with all patients reaching MRD-negative status by cycle 3 with no major safety concerns. He also shared findings from an ongoing Phase 1b trial evaluating the safety and early efficacy of a combination therapy of ivosidenib and ruxolitinib in patients with advanced IDH1-mutated myeloproliferative neoplasms. Caner Saygin, MD , Assistant Professor of Medicine at UChicago Medicine, presented interim results from an ongoing Phase I/II trial investigating the safety and efficacy of a novel combination therapy – LP-118 (a dual BCL-2/BCL-xL inhibitor), pinatinib, vincristine, and dexamethasone for adults with relapsed/refractory T-ALL/lymphoblastic lympohoma. The regimen targets pre-T-cell receptor-signaling pathways with the goal of improving survival outcomes in this difficult-to-treat population. T-cell engaging (TCE) therapies, including CAR T-cells and bispecific antibodies, have significantly transformed care for patients with B-cell non-Hodgkin lymphoma (B-NHL) because of increasing approvals and use in earlier lines of therapy. In an education session, Sonali Smith, MD , Elwood V. Jensen Professors of Medicine and Chief of the Section of Hematology/Oncology, addressed ongoing challenges with these therapies, such as toxicity, logistical complexity and accessibility. She discussed MRD-based strategies for patient selection and the integration of emerging platforms like CAR-NK and TCR-T cells to expand therapeutic potential. Finally, in a special scientific symposium, Jeffrey Rathmell, PhD , Virginia and D. K. Ludwig Chair and Professor for Cancer Research in University of Chicago's Ben May Department of Cancer Research, discussed how metabolic pathways regulate immune cell function. It focused on mitochondria responses to chronic inflammation and cellular stress – key factors shaping immune system behavior. With thousands of abstracts, live sessions and collaborative learning opportunities, ASH 2025 once again affirmed its role as the world’s leading hematology conference. UChicago Medicine’s robust presence showcased its commitment to advancing the science and clinical care of hematologic diseases through excellence in research, education and innovation. The next ASH Annual Meeting and Exposition will be held December 12–15, 2026, in New Orleans. Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Key combination for the treatment of Small Cell Lung CancerMADRID and CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced that the Japanese Patent Office has issued a Decision to Grant for its patent application JP2021-557187, entitled “Combinations of iadademstat for cancer therapy”. Following formal grant, the patent is expected to remain in force until at least 2040, excluding any available patent term extensions. With this decision, Oryzon has now secured patent protection for these combinations in Europe, Japan, Australia and Russia, while corresponding patent applications continue to be prosecuted in other countries. “This Japanese grant represents another important milestone in building a robust patent portfolio around iadademstat,” said Neus Virgili, Oryzon’s Chief IP Officer. “It reinforces our strategy to protect the clinical use of iadademstat in combination with immune checkpoint inhibitors such as atezolizumab and durvalumab in small cell lung cancer (SCLC), an approach we are evaluating as part of iadademstat’s ongoing clinical development programs.” Iadademstat is being evaluated in combination with PD-L1 inhibitors (atezolizumab or durvalumab) in first line, extensive-disease SCLC patients in an ongoing Phase I/II trial conducted and sponsored by the U.S. National Cancer Institute (NCI) under a Cooperative Research and Development Agreement (CRADA) with Oryzon. The study is carried out at more than 30 clinical sites across the United States, including leading cancer institutions such as Memorial Sloan Kettering Cancer Center, Johns Hopkins, City of Hope, Yale University and the University of Chicago, among others. About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS (Phase III-ready) and iadademstat in oncology/hematology (Phase II). The company has other pipeline assets directed against other epigenetic targets like HDAC-6 where a clinical candidate ORY-4001, has been nominated for its possible development in CMT and ALS. In addition, Oryzon has a strong platform for biomarker identification and target validation for a variety of malignant and neurological diseases. For more information, visit www.oryzon.com About IadademstatIadademstat (ORY-1001) is a small oral molecule, which acts as a highly selective inhibitor of the epigenetic enzyme LSD1 and has a powerful differentiating effect in hematologic cancers (see Maes et al., Cancer Cell 2018 Mar 12; 33 (3): 495-511.e12.doi: 10.1016 / j.ccell.2018.02.002.). A FiM Phase I/IIa clinical trial with iadademstat in R/R AML patients demonstrated the safety and good tolerability of the drug and preliminary signs of antileukemic activity, including a CRi (see Salamero et al, J Clin Oncol, 2020, 38(36): 4260-4273. doi: 10.1200/JCO.19.03250). Iadademstat has shown encouraging safety and strong clinical activity in combination with azacitidine in a Phase IIa trial in elder 1L AML patients (ALICE trial) (see Salamero et al., ASH 2022 oral presentation & The Lancet Haematology, 2024, 11(7):e487-e498). Iadademstat is currently being evaluated in combination with azacitidine and venetoclax in 1L AML in an investigator-initiated study (IIS) led by OHSU and in combination with gilteritinib in the company-sponsored Phase Ib FRIDA trial in relapsed/refractory FLT3-mutant AML, with highly encouraging preliminary safety and efficacy data recently reported at ASH-2025 for both trials: 100% ORR and 90% strict CR in 1L AML, and 67% CCR (at the dose under expansion) in R/R AML. Additional studies in hemato-oncology include an IIS in MDS, and trials in myeloproliferative neoplasms and 1L AML both sponsored by the U.S. National Cancer Institute (NCI) under the Cooperative Research and Development Agreement (CRADA) signed between Oryzon and the NCI to collaborate on further clinical development of iadademstat in different types of hematologic and solid cancers. Beyond hematological cancers, the inhibition of LSD1 has been proposed as a valid therapeutic approach in some solid tumors such as small cell lung cancer (SCLC), neuroendocrine tumors (NET), medulloblastoma and others. In a Phase IIa trial in combination with platinum/etoposide in second line ED-SCLC patients (CLEPSIDRA trial), preliminary activity and safety results have been reported (see Navarro et al., ESMO 2018 poster). Iadademstat is in a Phase I/II randomized trial in 1L ED-SCLC in combination with ICI sponsored by NCI and led by the Memorial Sloan Kettering Cancer Center. In addition, Oryzon is expanding iadademstat’s clinical development into non-oncological hematology indications, with trials in sickle cell disease (approved by EMA, enrolling) and essential thrombocythemia (submitted to EMA). Iadademstat has orphan drug designation for SCLC in the US and for AML in the US and EU. FORWARD-LOOKING STATEMENTSThis communication contains, or may contain, forward-looking information and statements about Oryzon, including financial projections and estimates and their underlying assumptions, statements regarding plans, objectives, and expectations with respect to future operations, capital expenditures, synergies, products and services, and statements regarding future performance. Forward-looking statements are statements that are not historical facts and are generally identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates” and similar expressions. Although Oryzon believes that the expectations reflected in such forward-looking statements are reasonable, investors and holders of Oryzon shares are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Oryzon that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include those discussed or identified in the documents sent by Oryzon to the Spanish Comisión Nacional del Mercado de Valores (CNMV), which are accessible to the public. Forward-looking statements are not guarantees of future performance and have not been reviewed by the auditors of Oryzon. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date they were made. All subsequent oral or written forward-looking statements attributable to Oryzon or any of its members, directors, officers, employees, or any persons acting on its behalf are expressly qualified in their entirety by the cautionary statement above. All forward-looking statements included herein are based on information available to Oryzon on the date hereof. Except as required by applicable law, Oryzon does not undertake any obligation to publicly update or revise any forward‐looking statements, whether as a result of new information, future events, or otherwise. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017, and/or the restated text of the Securities Market Law, approved by Law 6/2023 of 17 March, and its implementing regulations. Nothing in this document constitutes investment advice. In addition, this document does not constitute an offer of purchase, sale or exchange, nor a request for an offer of purchase, sale or exchange of securities, nor a request for any vote or approval in any jurisdiction. The shares of Oryzon Genomics, S.A. may not be offered or sold in the United States of America except pursuant to an effective registration statement under the Securities Act of 1933 or pursuant to a valid exemption from registration.. Spain Oryzon IR & Media, Europe & US Patricia Cobo/Mario Cordera Emili Torrell Sandya von der Weid Atrevia Chief BD Officer LifeSci Advisors, LLC +34 91 564 07 25 +34 673 33 97 65 +34 93 515 1313 +41 78 680 05 38 pcobo@atrevia.com mcordera@atrevia.com etorrell@oryzon.com svonderweid@lifesciadvisors.com